3Rd Quarter 2001 Bulletin

Total Page:16

File Type:pdf, Size:1020Kb

3Rd Quarter 2001 Bulletin In This Issue... Promoting Colorectal Cancer Screening Important Information and Documentaion on Promoting the Prevention of Colorectal Cancer ....................................................................................................... 9 Intestinal and Multi-Visceral Transplantation Coverage Guidelines and Requirements for Approval of Transplantation Facilities12 Expanded Coverage of Positron Emission Tomography Scans New HCPCS Codes and Coverage Guidelines Effective July 1, 2001 ..................... 14 Skilled Nursing Facility Consolidated Billing Clarification on HCPCS Coding Update and Part B Fee Schedule Services .......... 22 Final Medical Review Policies 29540, 33282, 67221, 70450, 76090, 76092, 82947, 86353, 93922, C1300, C1305, J0207, and J9293 ......................................................................................... 31 Outpatient Prospective Payment System Bulletin Devices Eligible for Transitional Pass-Through Payments, New Categories and Crosswalk C-codes to Be Used in Coding Devices Eligible for Transitional Pass-Through Payments ............................................................................................ 68 Features From the Medical Director 3 he Medicare A Bulletin Administrative 4 Tshould be shared with all General Information 5 health care practitioners and managerial members of the General Coverage 12 provider/supplier staff. Hospital Services 17 Publications issued after End Stage Renal Disease 19 October 1, 1997, are available at no-cost from our provider Skilled Nursing Facility Services 22 Web site at Comprehensive Outpatient www.floridamedicare.com. Rehabilitation Facilities 25 Routing Suggestions: Critical Access Hospitals 26 ! Medicare Manager Fraud and Abuse 27 Provider Audit and Reimbursement 29 ! Reimbursement Director Electronic Data Interchange 30 ! Chief Financial Officer Local and Focused Medical Policies 31 ! Compliance Officer Outpatient Prospective Payment Services 68 ! DRG Coordinator ! ________________ FIRST COAST ! ________________ Medicare A Health Care Financing Administration SERVICE OPTIONS, INC. ! ________________ A Newsletter for Florida Medicare Part Providers A HCFA Contracted Carrier & Intermediary Third Quarter 2001 Volume 3, Number 3 TABLE OF CONTENTS Table of Contents Medicare A In This Issue ................................................. 1 Electronic Data Interchange Bulletin From the Intermediary Medical Director Elimination of HCFA Free Billing Software ........ 30 Vol. 3, No. 3 A Physician’s Focus Medical Policies Third Quarter Medicare Coverage of Drugs and Biologicals, Medical Policy Table of Contents ................. 31 2001 Payment Methodologies and Ethical Use of the American Medical Association’s Obligations of Health Care Professionals ... 3 (AMA’s) Current Procedural Terminology Publications Staff Administrative (CPT) Codes on Contractors’ Web Sites .. 31 Millie C. Pérez About The Medicare A Bulletin ....................... 4 Final Medical Policies Pauline Crutcher New Toll-Free Numbers Available .................. 4 29540: Strapping ........................................... 32 Shari Bailey Bill Angel General Information 33282: Insertable Loop Recorder .................... 34 67221: Ocular Photodynamic Therapy (OPT) Payment Revisions for Diagnostic and The Medicare A Bulletin is with Verteporfin ................................. 36 published bimonthly by the Screening Mammograms Performed 70450: Computerized Tomography Scans ....... 38 Medicare Publications with New Technologies ........................... 5 76090: Diagnostic Mammography ................ 42 Department, to provide Suspension of Requirements to Register for 76092: Screening Mammograms ................. 44 timely and useful Receiving Contractor’s Notification ............ 6 82947: Blood Glucose Testing ........................ 46 information to Medicare Elimination of Time Limit on Medicare Benefits Part A providers in Florida. 86353: Lymphocyte Transformation ............. 49 for Immunosuppressive Drugs ................. 6 93922: Noninvasive Physiologic Studies of Overpayment Interest Rate ............................ 6 Questions concerning this Upper or Lower Extremity Arteries ...... 51 Q & A Regarding Payment for the Services of publication or its contents C1300: Hyperbaric Oxygen Therapy ............ 54 may be directed in writing Therapy Students under Part A of Medicare 6 C1305: Apligraf® (Graftskin) ........................ 59 to: BIPA Changes to the Payment for DMEPOS .. 7 J0207: Amifostine (Ethyol®) ..........................62 Cervical Cancer Awareness and the Benefits Medicare Part A J9293: Mitoxantrone Hydrocloride ................ 64 of Pap Tests .......................................... 8 Publications Promoting Colorectal Cancer Screening ......... 9 Additions and Revisions to Previously P.O. Box 2078 Colorectal Cancer Screening Campaign Print Published Medical Policy Jacksonville, FL Materials ............................................. 10 70544: Magnetic Resonance Angiography ... 66 32231-0048 Some Important Facts You Should Know 82435: Chloride .......................................... 66 CPT five-digit codes, about Colorectal Cancer ........................ 11 82728: Serum Ferritin .................................... 66 descriptions, and other data 94010: Spirometry ....................................... 66 only are copyright 1999 by General Coverage J1561: Intravenous Immune Globulin ........... 66 American Medical New CLIA Waived Tests .............................. 12 J9999: Doxorubicin HCL—Antineoplastic Association (or such other date of publication of CPT). Intestinal and Multi-Visceral Transplantation .. 12 Drug Policy ....................................... 66 Expanded Coverage of PET Scans and All Rights Reserved. LMRP Development Changes ..................... 67 Related Claims Processing Changes .... 14 Applicable FARS/DFARS Verteporfin .................................................... 16 Outpatient Prospective Payment System apply. No fee schedules, basic units, relative values or Hospital Services Devices Eligible for Transitional Pass-Through related listings are included Payment ............................................. 68 Postacute Care Transfer Policy .................... 17 in CPT. AMA does not Independent Laboratory Billing for the TC of Categories for Use in Coding Devices Eligible directly or indirectly Physician Pathology Services to Hospital for Transitional Pass-Through Payment .. 80 practice medicine or Patients ............................................... 18 General Coding, Billing Instructions and dispense medical services. Explanations for Categories Used in AMA assumes no liability for End of Stage Renal Disease Coding Devices Eligible for Transitional data contained or not End of Stage Renal Disease Drug Pricing Pass-Through Payment ....................... 82 contained herein. Update ................................................. 19 C-Codes for Categories Used in Coding ICD-9-CM codes and their Devices Eligible for Transitional Pass- descriptions used in this Skilled Nursing Facility Services Through Payment ................................ 84 publication are copyright Clarification and HCPCS Coding Update: Part Crosswalk to New Category C-codes Used in 1998 under the Uniform B Fee Schedule and Consolidated Billing . 22 Coding Devices Eligible for Transitional Copyright Convention. All Delay in Edit Implementation Consolidated Pass-Through Payments ........................ 85 rights reserved. Billing for SNF Residents ...................... 24 Further Guidance Regarding Billing under the Third-party websites. This Comprehensive Outpatient OPPS ................................................. 106 document contains Rehabilitation Facility Services Procedures Subject to Home Health references to sites operated Consolidated Billing .............................. 108 by third parties. Such Expansion of Moratorium on the Application references are provided for of the $1,500.00 Financial Limitation for Educational Resources your convenience only. Outpatient Rehabilitation services ........... 25 HCFA Announces Revised Fee Policy in Fiscal BCBSF and/or FCSO do not control such sites and are not Critical Access Hospitals Year 2001 for Provider Education and Training Activities ................................. 109 responsible for their content. Clinical Diagnostic Laboratory Tests Furnished The inclusion of these by Critical Access Hospitals .................... 26 www.floridamedicare.com—Florida Medicare’s references within this Salary Equivalency Guidelines Update Factors 26 Provider Web Site ................................ 109 document does not suggest Order Form - Part A Materials .................... 110 any endorsement of the Fraud and Abuse material on such sites or any Fraud and Abuse in the Medicare Program ...... 27 Other Information association with their Addresses, Medicare Web sites, operators. Provider Audit and Reimbursement and Phone Numbers ........................... 111 Hospital Payments and Disproportionate Share Hospital Thresholds ................................ 29 2 The Florida Medicare A Bulletin Third Quarter 2001 FROM THE INTERMEDIARY MEDICAL DIRECTOR A PHYSICIAN’S FOCUS Medicare Coverage of Drugs and Biologicals, Payment Methodologies, and Ethical Obligations of Health Care Professionals hough the Medicare Program insures nearly one in seven TAmericans, its current benefit package is not as comprehensive as most private insurance plans. Drug coverage, especially
Recommended publications
  • Chlorhexidine Soap Instructions
    Pre-Operative Bathing Instructions Infection Prevention Because skin is not sterile, we need to be sure that your skin is as free of germs as possible before your admission. You can reduce the number of germs on your skin and decrease the risk of surgical site infection by preparing your skin with a special soap called chlorhexidine gluconate (CHG). The instructions for use are attached. What is CHG? CHG is a chemical antiseptic that is effective on both gram-positive and gram-negative bacteria. It is both bacteriocidal (kills) and bacteriostatic (stops reproductions) of any bacteria on the skin. CHG is in several products such as mouthwash, contact lens solution, wound wash, acne skin wash topical skin cleansers (chloraprep-what is used to clean your skin before an IV), thus we do not expect using this soap will cause skin irritation but please speak with your primary care physician to discuss any allergies. Studies show that repeated use of CHG soap enhances the ability of CHG to reduce bacterial counts on the skin; not only during the immediate period after the shower, but for a number of hours afterward. Studies suggest that patients may benefit from bathing or showering with CHG soap for at least 3 days before surgery in order to achieve the most benefit. It is unknown whether using CHG soap for less than or more than 3 days is beneficial. We recommend 3 days of treatment but understand this is not always possible and bathing the night before and the day of using CHG is acceptable. CHG soap can be purchased at any local pharmacy.
    [Show full text]
  • Health Evidence Review Commission's Value-Based Benefits Subcommittee
    Health Evidence Review Commission's Value-based Benefits Subcommittee September 28, 2017 8:00 AM - 1:00 PM Clackamas Community College Wilsonville Training Center, Room 111-112 29373 SW Town Center Loop E, Wilsonville, Oregon, 97070 Section 1.0 Call to Order AGENDA VALUE-BASED BENEFITS SUBCOMMITTEE September 28, 2017 8:00am - 1:00pm Wilsonville Training Center, Rooms 111-112 29353 SW Town Center Loop E Wilsonville, Oregon 97070 A working lunch will be served at approximately 12:00 PM All times are approximate I. Call to Order, Roll Call, Approval of Minutes – Kevin Olson 8:00 AM II. Staff report – Ariel Smits, Cat Livingston, Darren Coffman 8:05 AM A. Chronic Pain Task Force meeting report B. Errata C. Retreat III. Straightforward/Consent agenda – Ariel Smits 8:15 AM A. Consent table B. Straightforward Modifications to the Prioritized List Changes: Continuous Glucose Monitoring in Diabetes Mellitus C. Straightforward changes to the PPI guideline for Barrett’s esophagus with dysplasia D. Tobacco cessation guideline clarification IV. Advisory Panel reports 8:25 AM A. OHAP 1. 2018 CDT code placement recommendations V. Previous discussion items 8:30 AM A. Consideration for prioritization on lines 500/660, Services with Minimal or No Clinical Benefit and/or Low Cost-Effectiveness 1. New medications for the treatment of Duchenne muscular dystrophy i. deflazacort (Emflaza) ii. etepliren (Exondys 51) VI. New discussion items 9:30 AM A. Testicular prostheses B. Capsulorrhaphy for recurrent shoulder dislocation C. Transcutaneous neurostimulators D. Physical therapy for interstitial cystitis E. Acute peripheral nerve injuries F. SOI on role of Prioritized List in Coverage G.
    [Show full text]
  • Investigation Study Radiation Profile on a 20 Gbq Therasphere Dose Vial
    Attachment 14 NUCLEAR MEDICINE M Nordion KANATA OPERATIONS INVESTIGATION STUDY PD99099003.08 Page No: I of 4 Investigation Study Radiation Profile on a 20 GBq TheraSphere Dose Vial I Signatures Prepared by: Date: ý - Al -; Approved by:. Date: 2•-O--c "Y (Richard Decaire CAHT) Document History Date Version''• •Comments Prepared by . Reviewed by Approved by PD99099003.08 Page Investigation No: 2 of 4 Study Radiation Profile on a 20 GBq TheraSphere Dose Vial 1. INTRODUCTION The United States Nuclear Regulatory Commission had requested information to support MDS Nordion application for the registration of TheraSphere. This request is contained in a letter dated November 23, 1999 from a Dr John P. Jankovich. This report contains data collected to address question 7 parts a, b, and c. The question poised is as follows: "Regarding external radiation levels, NRC needs information on the device itself, not on the radiation levels around the patient as addressed in the application. Therefore, please specify: a. External radiation levels around the lucite vial containing the maximum dose of 20 GBq (540 mCi). Provide the data, preferably, at the surface, and at 5, 30, and 100 cm. If there are no meaningful readings at these locations, please state so. b. Provide similar external radiation levels, if any, outside the lead pot with the lucite vial inside containing a maximum dose of microspheres. c. Please specify the instrument which you used to perform the radiation profile measurements by listing the instrument manufacturers, model numbers, calibration dates, sensitivity, etc." To address these questions, information was provided from previous development work.
    [Show full text]
  • Hereditary Gingival Fibromatosis CASE REPORT
    Richa et al.: Management of Hereditary Gingival Fibromatosis CASE REPORT Hereditary Gingival Fibromatosis and its management: A Rare Case of Homozygous Twins Richa1, Neeraj Kumar2, Krishan Gauba3, Debojyoti Chatterjee4 1-Tutor, Unit of Pedodontics and preventive dentistry, ESIC Dental College and Hospital, Rohini, Delhi. 2-Senior Resident, Unit of Pedodontics and preventive dentistry, Oral Health Sciences Centre, Post Correspondence to: Graduate Institute of Medical Education and Research , Chandigarh, India. 3-Professor and Head, Dr. Richa, Tutor, Unit of Pedodontics and Department of Oral Health Sciences Centre, Post Graduate Institute of Medical Education and preventive dentistry, ESIC Dental College and Research, Chandigarh, India. 4-Senior Resident, Department of Histopathology, Oral Health Sciences Hospital, Rohini, Delhi Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India. Contact Us: www.ijohmr.com ABSTRACT Hereditary gingival fibromatosis (HGF) is a rare condition which manifests itself by gingival overgrowth covering teeth to variable degree i.e. either isolated or as part of a syndrome. This paper presented two cases of generalized and severe HGF in siblings without any systemic illness. HGF was confirmed based on family history, clinical and histological examination. Management of both the cases was done conservatively. Quadrant wise gingivectomy using ledge and wedge method was adopted and followed for 12 months. The surgical procedure yielded functionally and esthetically satisfying results with no recurrence. KEYWORDS: Gingival enlargement, Hereditary, homozygous, Gingivectomy AA swollen gums. The patient gave a history of swelling of upper gums that started 2 years back which gradually aaaasasasss INTRODUCTION increased in size. The child’s mother denied prenatal Hereditary Gingival Enlargement, being a rare entity, is exposure to tobacco, alcohol, and drug.
    [Show full text]
  • Coronary Artery Perforation
    Published online: 2019-09-20 THIEME 110 InterventionalCoronary Artery Rounds Perforation Deb et al. Coronary Artery Perforation Tripti Deb1 Jyotsna Maddury2 Prasant Kr. Sahoo3 1Department of Interventional Cardiology, Apollo Hospitals, Address for correspondence Jyotsna Maddury, MD, DM, FACC, Hyderabad, Telangana, India Department of Cardiology, Nizam’s Institute of Medical Sciences 2Department of Cardiology, Nizam’s Institute of Medical Sciences (NIMS), Punjagutta, Hyderabad, Telangana 500082, India (NIMS), Punjagutta, Hyderabad, India (e-mail: [email protected]). 3Department of Interventional Cardiology, Apollo Hospitals, Bhubaneswar, Odisha, India Ind J Car Dis Wom 2019;4:110–120 Abstract Percutaneous coronary intervention (PCI) is considered as the standard treatment of obstructive coronary artery disease in indicated patients. Even though PCI gives symp- Keywords tomatic angina improvement, but associated with serious complications like coronary ► coronary artery artery perforation (CAP), the incidence is quite low. With the more complex lesions for perforation successful angioplasty, different devices are required, which in turn increase the inci- ► percutaneous coro- dence of CAP in these patients. Here we review the classification, incidence, pathogen- nary intervention esis, clinical sequela, risk factors, predictors, and management of CAP in the current ► coronary artery era due to PCI. perforation ► management of coro- nary perfusion Introduction Consequences of Coronary Artery Perforation Percutaneous coronary intervention (PCI) for obstructive coronary artery diseases is accepted and has standardized Consequences of CAP depend on the location and severity. procedure with minimal complication rates, including iat- Location wise, if CAP occurs to the right or left ventricle, if not rogenic coronary artery perforation (CAP). Although angio- massive, then usually no immediate clinical consequences graphically significant coronary artery dissection is known occur.
    [Show full text]
  • Being Aware of Chlorhexidine Allergy
    Being aware of chlorhexidine allergy If you have an immediate allergic reaction to chlorhexidine you may experience symptoms such as: x itching x skin rash (hives) x swelling x anaphylaxis. People who develop anaphylaxis to chlorhexidine may have experienced mild reactions, such as skin rash, to chlorhexidine before. Irritant contact dermatitis or allergic contact dermatitis Chlorhexidine can also cause irritant dermatitis. This is not a true allergic reaction. It is caused by chlorhexidine directly irritating skin and results in rough, dry and scaly Chlorhexidine is an antiseptic. Allergic reactions to skin, sometimes with weeping sores. chlorhexidine are rare but are becoming more common. Chlorhexidine is used in many products both in Chlorhexidine can also cause allergic contact hospitals and in the community. dermatitis. Symptoms look like irritant dermatitis, but the cause of the symptoms is delayed by 12-48 hours Why have I been given this factsheet? after contact with chlorhexidine. You have been given this brochure because you have had a reaction to a medication, a medical dressing Both irritant dermatitis and allergic contact dermatitis or antiseptic. This may or may not be caused by a caused by chlorhexidine are annoying but not chlorhexidine allergy. dangerous. It is important that you are aware of the possibility of an It is recommended that you avoid chlorhexidine if you allergy. experience these responses as some people have gone on to develop immediate allergic reaction to chlorhexidine. Allergic reactions to chlorhexidine Severe allergic reactions to chlorhexidine are rare, but How do I know which products contain they can be serious. Immediate allergic reactions can chlorhexidine? cause anaphlaxis (a very severe allergic reaction which can be life-threatening).
    [Show full text]
  • Exploring Vigilance Notification for Organs
    NOTIFY - E xploring V igilanc E n otification for o rgans , t issu E s and c E lls NOTIFY Exploring VigilancE notification for organs, tissuEs and cElls A Global Consultation e 10,00 Organised by CNT with the co-sponsorship of WHO and the participation of the EU-funded SOHO V&S Project February 7-9, 2011 NOTIFY Exploring VigilancE notification for organs, tissuEs and cElls A Global Consultation Organised by CNT with the co-sponsorship of WHO and the participation of the EU-funded SOHO V&S Project February 7-9, 2011 Cover Bologna, piazza del Nettuno (photo © giulianax – Fotolia.com) © Testi Centro Nazionale Trapianti © 2011 EDITRICE COMPOSITORI Via Stalingrado 97/2 - 40128 Bologna Tel. 051/3540111 - Fax 051/327877 [email protected] www.editricecompositori.it ISBN 978-88-7794-758-1 Index Part A Bologna Consultation Report ............................................................................................................................................7 Part B Working Group Didactic Papers ......................................................................................................................................57 (i) The Transmission of Infections ..........................................................................................................................59 (ii) The Transmission of Malignancies ....................................................................................................................79 (iii) Adverse Outcomes Associated with Characteristics, Handling and Clinical Errors
    [Show full text]
  • ICD~10~PCS Complete Code Set Procedural Coding System Sample
    ICD~10~PCS Complete Code Set Procedural Coding System Sample Table.of.Contents Preface....................................................................................00 Mouth and Throat ............................................................................. 00 Introducton...........................................................................00 Gastrointestinal System .................................................................. 00 Hepatobiliary System and Pancreas ........................................... 00 What is ICD-10-PCS? ........................................................................ 00 Endocrine System ............................................................................. 00 ICD-10-PCS Code Structure ........................................................... 00 Skin and Breast .................................................................................. 00 ICD-10-PCS Design ........................................................................... 00 Subcutaneous Tissue and Fascia ................................................. 00 ICD-10-PCS Additional Characteristics ...................................... 00 Muscles ................................................................................................. 00 ICD-10-PCS Applications ................................................................ 00 Tendons ................................................................................................ 00 Understandng.Root.Operatons..........................................00
    [Show full text]
  • Ventricular Long Axis Function: Amplitudes and Timings
    Umeå University Medical Dissertations New Series No 895 - ISSN 0346-6612 _______________________________________________________________ From the Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden Ventricular Long Axis Function: Amplitudes and Timings Echocardiographic Studies in Health and Disease Frederick Bukachi Umeå 2004 © Copyright: Frederick Bukachi ISBN 91-7305-661-8 Printed in Sweden by Solfjädern offset AB Umeå, 2004 To my family Frida, Anthony, Arnold and Maria Time brings wisdom to the mind and healing to the heart. Anonymous Table of contents Table of contents................................................................................................................. 1 Abstract ................ ............................................................................................................. 3 List of original studies ........................................................................................................4 Abbreviations...................................................................................................................... 5 1. Introduction............................................................................................................. 6 2. Ventricular long axis ............................................................................................... 6 2.1. General overview and historical perspective................................................ 6 2.2. Anatomy of long axis ..................................................................................
    [Show full text]
  • TAXUS™ Express 2 ™ Paclitaxel-Eluting
    TAXU S ® Express 2® Paclitaxel-Eluting Coronary Stent System Patient Information Guide Table of Contents Notes Coronary Artery Disease . 2 Who is at Risk? . .3 Diagnosis of Coronary Artery Disease . 3 Treatment of Coronary Artery Disease . 3 Angioplasty . 4 Coronary Artery Stents . 4 Restenosis . 5 Your Drug-Eluting Stent, the TAXUS ® Express 2® Paclitaxel-Eluting Coronary Stent System . 7 Drug-Eluting Stents . 7 The Express ® Stent Platform for the TAXUS ® Express ® Stent . 7 The Polymer Coating on the TAXUS Express Stent . 7 The Drug that is Released from the TAXUS Express Stent . 8 When should the TAXUS Express Stent NOT be Used . 8 What are the Risks & Potential Benefits of Treatment with the TAXUS Express Stent? . 9 Alternative Practices and Procedures . 11 The Angioplasty Procedure . 12 Preparation for the Procedure . 12 Angioplasty and Stent Placement Procedure . 12 Post-Treatment . 13 After the Procedure . 13 Activity . 14 Medications . 14 Follow-Up Examinations . 15 Magnetic Resonance Imaging (MRI) . 15 Frequently Asked Questions . 16 Glossary . 17 Patient Information Card . Inside Back Cover 1 Notes Coronary Artery Disease Coronary Artery Disease (CAD) is usually caused by atherosclerosis, and affects the coronary arteries that surround the heart. These coronary arteries supply blood with oxygen and other nutrients to the heart muscle to make it function properly. CAD occurs when the inner walls of the coronary arteries thicken due to a buildup of cholesterol, fatty deposits, calcium, and other elements. This material is known as plaque. As plaque develops, the vessel narrows. When the vessel narrows (for example with physical exertion or mental stress), Aorta blood flow through the vessel is reduced so less oxygen and Right Left other nutrients reach Coronary Coronary the heart muscle.
    [Show full text]
  • Variations in the Practice of Molecular Radiotherapy and Implementation Of
    Sjögreen Gleisner et al. EJNMMI Physics (2017) 4:28 EJNMMI Physics DOI 10.1186/s40658-017-0193-4 ORIGINAL RESEARCH Open Access Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey Katarina Sjögreen Gleisner1* , Emiliano Spezi2, Pavel Solny3, Pablo Minguez Gabina4, Francesco Cicone5, Caroline Stokke6, Carlo Chiesa7, Maria Paphiti8, Boudewijn Brans9, Mattias Sandström10, Jill Tipping11, Mark Konijnenberg12 and Glenn Flux13 * Correspondence: [email protected] Abstract 1Department of Medical Radiation Physics, Clinical Sciences Lund, Background: Currently, the implementation of dosimetry in molecular radiotherapy Lund University, Lund, Sweden (MRT) is not well investigated, and in view of the Council Directive (2013/59/Euratom), Full list of author information is there is a need to understand the current availability of dosimetry-based MRT in clinical available at the end of the article practice and research studies. The aim of this study was to assess the current practice of MRT and dosimetry across European countries. Methods: An electronic questionnaire was distributed to European countries. This addressed 18 explicitly considered therapies, and for each therapy, a similar set of questions were included. Questions covered the number of patients and treatments during 2015, involvement of medical specialties and medical physicists, implementation of absorbed dose planning, post-therapy imaging and dosimetry, and the basis of therapy prescription. Results: Responses were obtained from 26 countries and 208 hospitals, administering in total 42,853 treatments. The most common therapies were 131I-NaI for benign thyroid diseases and thyroid ablation of adults. The involvement of a medical physicist (mean over all 18 therapies) was reported to be either minority or never by 32% of the responders.
    [Show full text]
  • Bone Grafting, Its Principle and Application: a Review
    OSTEOLOGY AND RHEUMATOLOGY Open Journal PUBLISHERS Review Bone Grafting, Its Principle and Application: A Review Haben Fesseha, MVSc, DVM1*; Yohannes Fesseha, MD2 1Department of Veterinary Surgery and Diagnostic Imaging, School of Veterinary Medicine, Wolaita Sodo University, P. O. Box 138, Wolaita Sodo, Ethiopia 2College of Health Science, School of Medicine, Mekelle University, P. O. Box1871, Mekelle, Ethiopia *Corresponding author Haben Fesseha, MVSc, DVM Assistant Professor, Department of Veterinary Surgery and Diagnostic Imaging, School of Veterinary Medicine, Wolaita Sodo University, P. O. Box: 138, Wolaita Sodo, Ethiopia;; E-mail: [email protected] Article information Received: March 3rd, 2020; Revised: March 20th, 2020; Accepted: April 11th, 2020; Published: April 22nd, 2020 Cite this article Fesseha H, Fesseha Y. Bone grafting, its principle and application: A review. Osteol Rheumatol Open J. 2020; 1(1): 43-50. doi: 10.17140/ORHOJ-1-113 ABSTRACT Bone grafting is a surgical procedure that replaces missing bone through transferring bone cells from a donor to the recipient site and the graft could be from a patient’s own body, an artificial, synthetic, or natural substitute. Bone grafts and bone graft substitutes are indicated for a variety of orthopedic abnormalities such as comminuted fractures (due to car accidents, falling from a height or gunshot injury), delayed unions, non-unions, arthrodesis, osteomyelitis and congenital diseases (rickets, abnormal bone development) and are used to provide structural support and enhance bone healing. Autogenous, allogeneic, and artificial bone grafts are common types and sources of grafts and the advancement of allografts, synthetic bone grafts, and new operative techniques may have influenced the use of bone grafts in recent years.
    [Show full text]